WTA
BPMC

Washington Trust Advisors’s Blueprint Medicines BPMC Stock Holding History

Washington Trust Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31
Closed -$2K – 936
2022
Q1 		$2K Hold
31
– – ﹤0.01% 935
2021
Q4 		$3K Buy
+31
New +$3.24K ﹤0.01% 910

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Washington Trust Advisors's BPMC Position: Q2 2022 in Review

Washington Trust Advisors sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 31 shares — an estimated $2K sold.

Washington Trust Advisors first reported a position in BPMC in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • Washington Trust Advisors reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 31 Blueprint Medicines shares in Q2 2022, an estimated $2K.
  • Washington Trust Advisors first reported a position in Blueprint Medicines in Q4 2021 and held it in 2 quarters.
  • Washington Trust Advisors's Blueprint Medicines position peaked at $3K in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Washington Trust Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.